Ipsen said it is voluntarily withdrawing Tazverik (tazemetostat) in all indications from all of its markets. The decision follows emerging data from the Phase Ib/III SYMPHONY-1 trial, where an independent monitoring committee cited adverse events involving secondary hematologic malignancies. Ipsen is stopping tazemetostat treatment for all SYMPHONY-1 participants, who will continue on lenalidomide plus rituximab only. The company is also discontinuing all active tazemetostat clinical trials and expanded access programs. Ipsen said it is working with the FDA on next steps to execute the withdrawal in the U.S., where Tazverik had accelerated approvals in follicular lymphoma and epithelioid sarcoma.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ipsen SA published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603090200PRIMZONEFULLFEED1001168853) on March 09, 2026, and is solely responsible for the information contained therein.